250275-22-0

Basic information

• Product Name: Carbamic acid, [(3R,4R)-4-methyl-3-piperidinyl]-, 1,1-dimethylethyl ester (9CI)
• Synonyms: tert-butyl N-[(3R,4R)-4-methylpiperidin-3-yl]carbamate;(3R,4R)-3-(Boc-amino)-4-methylpiperidine;Carbamic acid, [(3R,4R)-4-methyl-3-piperidinyl]-, 1,1-dimethylethyl ester (9CI);Tert-Butyl ((3R,4R)-4-Methylpiperidin-3-Yl)Carbamate(WXC02333)
• CAS NO: 250275-22-0
• Molecular Formula: C11H22N2O2
• Molecular Weight: 214.30458
• Product Categories: N-BOC
• Mol File: 250275-22-0.mol
• Article Data: 8

Chemical Properties

• Boiling Point: 313.4±31.0 °C(Predicted)
• Appearance: /
• Density: 1.00±0.1 g/cm3(Predicted)
• PKA: 12.39±0.40(Predicted)
• CAS DataBase Reference: Carbamic acid, [(3R,4R)-4-methyl-3-piperidinyl]-, 1,1-dimethylethyl ester (9CI)(CAS DataBase Reference)
• NIST Chemistry Reference: Carbamic acid, [(3R,4R)-4-methyl-3-piperidinyl]-, 1,1-dimethylethyl ester (9CI)(250275-22-0)
• EPA Substance Registry System: Carbamic acid, [(3R,4R)-4-methyl-3-piperidinyl]-, 1,1-dimethylethyl ester (9CI)(250275-22-0)

Safety Data

• Hazardous Substances Data: 250275-22-0(Hazardous Substances Data)

Usage

General Description

Carbamic acid, [(3R,4R)-4-methyl-3-piperidinyl]-, 1,1-dimethylethyl ester (9CI) is a chemical compound with the molecular formula C11H22N2O2. It is an ester of carbamic acid and is derived from the combination of 3R,4R-4-methyl-3-piperidinyl and 1,1-dimethylethyl groups. Carbamic acid, [(3R,4R)-4-methyl-3-piperidinyl]-, 1,1-dimethylethyl ester (9CI) is commonly used as an intermediate in the synthesis of various pharmaceuticals and agrochemicals. It is also known for its potential as a central nervous system stimulant and as an anti-tuberculosis drug. The 9CI in its name refers to the identifier code assigned in the Chemical Abstracts Service (CAS) registry. Overall, Carbamic acid, [(3R,4R)-4-methyl-3-piperidinyl]-, 1,1-dimethylethyl ester (9CI) has important applications in the field of medicinal chemistry and drug development.

Upstream product

• 180253-66-1 3-(tert-butyloxycarbonylamino)-4-methyl-pyridine 
• 24424-99-5 di-tert-butyl dicarbonate 
• 3430-27-1 3-amino-4-methylpyridine 
• 444188-89-0 7-(diethoxyphosphoryl)-3,7-diazabicyclo[4.1.0]heptane-3-carboxylic acid benzyl ester 
• 174681-58-4 5,6-dihydropyridine-1(2H)-carboxylate 
• 66207-08-7 3,4-epoxy-piperidine-1-carboxylic acid benzyl ester 

Downstream Products

• 1405127-46-9 N-(4-((3S_.4S)-3-amino-4-methylpiperidin-1-yl)pyridin-3-yl)-2-(2,6-difluorophenyl)imidazo[1,5-b]pyridazin-7-amine 
• 1405129-25-0 tert-butyl ((3S,4R)-1-(3-((2-(2,6-difluorophenyl)imidazo[1,5-b]pyridazin-7-yl)amino)pyridin-4-yl)-4-methylpiperidin-3-yl)carbamate 
• 1405127-50-5 N-(4-((3S,4R)-3-amino-4-methylpiperidin-1-yl)pyridin-3-yl)-2-(2,6-difluorophenyl)imidazo[1,5-b]pyridazin-7-amine 

Relevant articles and documents

Discovery of imidazopyridazines as potent Pim-1/2 kinase inhibitors

High levels of Pim expression have been implicated in several hematopoietic and solid tumor cancers, suggesting that inhibition of Pim signaling could provide patients with therapeutic benefit. Herein, we describe our progress towards this goal using a screening hit (rac-1) as a starting point. Modification of the indazole ring resulted in the discovery of a series of imidazopyridazine-based Pim inhibitors exemplified by compound 22m, which was found to be a subnanomolar inhibitor of the Pim-1 and Pim-2 isoforms (IC50values of 0.024?nM and 0.095?nM, respectively) and to potently inhibit the phosphorylation of BAD in a cell line that expresses high levels of all Pim isoforms, KMS-12-BM (IC50?=?28?nM). Profiling of Pim-1 and Pim-2 expression levels in a panel of multiple myeloma cell lines and correlation of these data with the potency of compound 22m in a proliferation assay suggests that Pim-2 inhibition would be advantageous for this indication.

HETEROCYCLIC TYROSINE KINASE INHIBITORS

The present invention provides compounds useful as inhibitors of Tec family kinases, compositions thereof, and methods of using the same. In certain embodiments, the present invention provides pharmaceutical formulations comprising provided compounds. In certain embodiments, the present invention provides a method of decreasing enzymatic activity of a Tec kinase family member. In some embodiments, such methods include contacting a Tec kinase family member with an effective amount of a Tec kinase family member inhibitor. In certain embodiments, the present invention provides a method of treating a disorder responsive to Tec kinase family inhibition in a subject in need thereof.

IMIDAZOPYRIDINE DERIVATIVES AS JAK INHIBITORS

New imidazopyridine derivatives having the chemical structure of formula (I) are disclosed; as well as process for their preparation, pharmaceutical compositions comprising them and their use in therapy as inhibitors of Janus Kinases (JAK).